In addition, dipeptidyl peptidase 4 (DPP-4), a drug that inhibits the degradation of GLP-1, reduces kidney damage through antiapoptotic, immunological, and antioxidative changes (Glorie et al., 2012). Here, DPP4 is linked to Nephropathy.